Endo Int'l Reports Top-line Results From Phase 2 Study Of CCH For Adhesive Capsulitis Of Shoulder

RTTNews | 1103 days ago
Endo Int'l Reports Top-line Results From Phase 2 Study Of CCH For Adhesive Capsulitis Of Shoulder

(RTTNews) - Pharmaceutical company Endo International plc (ENDP) announced Friday top-line results from its Phase 2 study of Collagenase Clostridium Histolyticum (CCH) in participants with adhesive capsulitis (AC) of the shoulder, commonly known as "frozen shoulder."

The Phase 2 study participants receiving up to three doses of CCH showed some improvement in the change from baseline in the adapted American Shoulder and Elbow Surgeons (ASES) Standardized Shoulder Form composite score for the affected shoulder at the Day 95 visit.

The difference compared to those study participants receiving placebo was not statistically significant.

The safety profile of CCH in the Phase 2 study was consistent with the known safety profile from other studies.

The Phase 2 trial enrolled 198 participants with unilateral idiopathic AC of the shoulder with restricted range of motion (ROM) and function in the affected shoulder. Participants were randomized 1:1 to receive CCH or placebo administered by ultrasound-guided injection.

read more
Endo Intl's Par Pharma Recalls Treprostinil Injection For Silicone Particulates

Endo Intl's Par Pharma Recalls Treprostinil Injection For Silicone Particulates

Dublin, Ireland -based Endo International plc announced that its operating company Par Pharmaceutical, Inc. is recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The recall, being conducted along with the U.S. Food and Drug Administration, is due to the potential for the presence of silicone particulates in the product solution.
RTTNews | 482 days ago
Endo International Says Health Canada Approves XCOPRI To Treat Epilepsy

Endo International Says Health Canada Approves XCOPRI To Treat Epilepsy

Specialty pharmaceutical company Endo International plc (ENDPQ.PK) announced Thursday that its operating company Paladin Labs, Inc. (PLB.TO) has received Health Canada's approval of XCOPRI (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
RTTNews | 740 days ago
Swiss Market Settles Marginally Up

Swiss Market Settles Marginally Up

Despite spending much of the day's trading session in negative territory, the Switzerland market closed marginally higher on Tuesday thanks to some brisk buying in the final minutes.
RTTNews | 1h 42min ago
European Markets Close On Positive Note

European Markets Close On Positive Note

European markets closed on a positive note on Tuesday, as investors shrugged off concerns about tariffs and picked up stocks, amid hopes major European countries will strike trade deals with the U.S. before the newly announced August 1 deadline.
RTTNews | 2h 4min ago